Table 2.
Follow-up data of inflammatory outcomes and Sofa score between study groups
| Variables (at day 7) | Group | Effect size** | P values of MD between groups | |
|---|---|---|---|---|
| Supplementation | Placebo | |||
| Sofa score | 3.00 (1.25) | 5.50 (5.75) | − 1.1 (L) | < 0.001 |
| Median (IQR) of change from baseline | − 3.50 (1.50) | − 2.00 (4.00) | ||
| P value | < 0.001 | 0.478 | ||
| WBC count, × 109/L | 9.30 (4.82) | 11.05 (3.55) | 0.3 (S) | 0.209 |
| Median (IQR) of change from baseline | 2.65 (4.10) | 3.50 (5.32) | ||
| P value | 0.001 | < 0.001 | ||
| Neutrophil count, × 109/L* | 71.32 (17.78) | 74.26 (11.15) | − 0.2 (S) | 0.494 |
| Mean change from baseline | − 6.40 (17.47) | − 3.97 (8.29) | ||
| P value | 0.054 | 0.014 | ||
| ESR* | 43. 83 (27.07) | 68.30 (35.89) | − 1.0 (L) | < 0.001 |
| Mean change from baseline | − 32.36 (19.68) | 0.60 (43.24) | ||
| P value | < 0.001 | 0.782 | ||
| CRP* | 34.00 (37.16) | 93.07 (56.08) | − 0.9 (L) | 0.001 |
| Mean change from baseline | − 64.10 (55.76) | − 12.76 (57.50) | ||
| P value | < 0.001 | 0.234 | ||
| IL6 | 86.80 (102.50) | 130.20 (254.25) | − 0.8 (M) | 0.003 |
| Median (IQR) of change from baseline | − 86.70 (92.10) | − 22.75 (105.62) | ||
| P value | < 0.001 | 0.045 | ||
| TNF-ɑ | 99.25 (80.72) | 144.95 (328.18) | − 0.6 (M) | 0.001 |
| Median (IQR) of change from baseline | − 96.00 (158.42) | − 20.70 (100.70) | ||
| P value | < 0.001 | 0.043 | ||
| IFN-γ | 38.00 (52.82) | 74.30 (114.60) | − 0.5 (S) | 0.089 |
| Median (IQR) of change from baseline | − 42.35 (77.42) | − 29.95 (102.75) | ||
| P value | < 0.001 | 0.016 | ||
WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IL6, interleukin-6; TNF-ɑ, tumor necrosis factor-ɑ; IFN-γ, interferon gamma; S, small: 0.2; M, moderate: 0.5; L, large: 0.8
*Normally distributed variables
**The effect sizes were calculated by Cohen’s d formula or Cliff’s delta statistic